REGENXBIO Corp (RGNX) Long-Term Debt to Capital Ratio

The development of gene therapy at REGENXBIO Inc. (RGNX) is independent of economic cycles, relying solely on the success of clinical trials. This chart illustrates the asset's market value on the GURU.Markets platform as 3.19. Business revenues are based on the licensing of patented gene delivery methods, while supply stability is ensured through international diversification and strict temperature control during component transportation.

Developing innovative gene therapies on the NAV platform requires significant capital expenditures, making the financing structure of REGENXBIO Inc. (RGNX) critical for sustainable growth. The current long-term debt-to-equity trend reflects the ratio of liabilities with maturities exceeding one year to equity, allowing investors to assess the degree of financial leverage and the resilience of capitalization to changes in Fed rates.